The role of rasagiline in the treatment of Parkinson’s disease
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affect...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-05-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/the-role-of-rasagiline-in-the-treatment-of-parkinsonrsquos-disease-peer-reviewed-article-CIA |
id |
doaj-8a3d0ef37dd64bfa898515d373301e9e |
---|---|
record_format |
Article |
spelling |
doaj-8a3d0ef37dd64bfa898515d373301e9e2020-11-25T01:02:24ZengDove Medical PressClinical Interventions in Aging1178-19982010-05-01Volume 51491564383The role of rasagiline in the treatment of Parkinson’s diseaseJulie Leegwater-KimElena BortanJulie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.Keywords: rasagiline, monoamine oxidase inhibitor, Parkinson’s diseasehttps://www.dovepress.com/the-role-of-rasagiline-in-the-treatment-of-parkinsonrsquos-disease-peer-reviewed-article-CIArasagilinemonoamine oxidase inhibitorParkinson's diseaseneuroprotection |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julie Leegwater-Kim Elena Bortan |
spellingShingle |
Julie Leegwater-Kim Elena Bortan The role of rasagiline in the treatment of Parkinson’s disease Clinical Interventions in Aging rasagiline monoamine oxidase inhibitor Parkinson's disease neuroprotection |
author_facet |
Julie Leegwater-Kim Elena Bortan |
author_sort |
Julie Leegwater-Kim |
title |
The role of rasagiline in the treatment of Parkinson’s disease |
title_short |
The role of rasagiline in the treatment of Parkinson’s disease |
title_full |
The role of rasagiline in the treatment of Parkinson’s disease |
title_fullStr |
The role of rasagiline in the treatment of Parkinson’s disease |
title_full_unstemmed |
The role of rasagiline in the treatment of Parkinson’s disease |
title_sort |
role of rasagiline in the treatment of parkinson’s disease |
publisher |
Dove Medical Press |
series |
Clinical Interventions in Aging |
issn |
1178-1998 |
publishDate |
2010-05-01 |
description |
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.Keywords: rasagiline, monoamine oxidase inhibitor, Parkinson’s disease |
topic |
rasagiline monoamine oxidase inhibitor Parkinson's disease neuroprotection |
url |
https://www.dovepress.com/the-role-of-rasagiline-in-the-treatment-of-parkinsonrsquos-disease-peer-reviewed-article-CIA |
work_keys_str_mv |
AT julieleegwaterkim theroleofrasagilineinthetreatmentofparkinsonrsquosdisease AT elenabortan theroleofrasagilineinthetreatmentofparkinsonrsquosdisease AT julieleegwaterkim roleofrasagilineinthetreatmentofparkinsonrsquosdisease AT elenabortan roleofrasagilineinthetreatmentofparkinsonrsquosdisease |
_version_ |
1725205257411100672 |